Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
OBJECTIVES:
* Assess the pharmacokinetics and tissue distribution of anti-CEA x anti-HSG bispecific monoclonal antibody TF2 in patients with colorectal cancer.
OUTLINE: This is a multicenter study.
Patients receive iodine I 131-labeled anti-CEA x anti-HSG bispecific monoclonal antibody TF2 (\^131I-TF2) IV over 10-20 minutes on day 1. Patients also undergo whole-body external scintigraphy at various times during the study.
Blood samples are collected at baseline and periodically after \^131I-TF2 infusion for pharmacokinetic studies and \^131I-TF2 biodistribution by ELISA and radioactivity measurements.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
DISEASE CHARACTERISTICS:
Histologically confirmed colorectal cancer
* Radiological documentation of disease is preferred, but not required
PATIENT CHARACTERISTICS:
Karnofsky performance status 70-100%
Life expectancy ≥ 3 months
WBC ≥ 3,000/mm³
Neutrophil count ≥ 1,500/mm³
Platelet count ≥ 100,000/mm³
Serum creatinine normal
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST/ALT \< 2 times ULN
Not pregnant or nursing
Fertile patients must use effective contraception during and for 1 month after completion of study therapy
No medical conditions that might prevent full participation in protocol-required testing or follow-up
No institutionalized patients (e.g., in prisons or mental health institutions)
PRIOR CONCURRENT THERAPY:
No concurrent chemotherapy or treatments that would compromise the safety and efficacy of protocol assessments
Clareo Health | Bispecific Antibody in Finding Tumor Cells in Patients With Colorectal Cancer
